Page 11 - CIRN Annual Report 2017-18

UPDATE FROM THE NETWORK LEAD
DR. JOANNE LANGLEY

The primary goal of the Clinical Trials partners at Merck across four diff erent clinical sites,
Network (CTN) is to increase the trial liaised with governments in three diff erent countries
capacity for Canadian researchers and to ensure ethics submissions and associated
provide the institutional infrastructure documentation were accurate, and planned the
where the lead for any one trial can be any logistics of transporting the vaccine and patient
member of the CTN, making it a truly pan- samples to and from Africa. This would not have been
Canadian network. The CTN currently has possible without the tireless eff orts of the project
systems and processes in place to support management team of Karen Inglis, May ElSherif,
investigators to address diverse questions. Jessica McCarthy and Donna MacKinnon-Cameron.

2017/18 was an important year for the CTN, with This year, the CTN welcomed new investigators, like
the culmination of years of work to start enrollment Guillaume Poliquin, who is leading an Ebola vaccine
for the fi rst African-Canadian collaboration for a study in Winnipeg for fi rst responders and laboratory
phase II Ebola vaccine in HIV-aff ected populations personnel who may come into contact with the virus.
study (ACHIV-Ebola). This collaboration between the
International Development Research Centre (IDRC), In 2018/19, the CTN has fi ve new trials beginning, two
CIRN and Merck began enrolling participants in 2018. led by Manish Sadarangani in British Columbia, one
led by Brenda Coleman in Toronto, and one led out of
Launching the ACHIV-Ebola trial has required, and Halifax.
will continue to require, a tremendous amount of work
behind the scenes. The CTN has coordinated with our

CO-INVESTIGATORS

Houreratou Barry Joanne Embree Allison McGeer Chris Sanders
Centre Muraz University of Winnipeg Mt. Sinai Hospital and Lakehead University
University of Toronto
Julie Bettinger Soren Gantt David Scheifele
BC Centre for Disease University of British Shelly McNeil University of British
Control, University of British Columbia Dalhousie University Columbia
Columbia
Scott Halperin Monika Naus Kathryn Slayter
Kristin Burnett Dalhousie University BC Centre for Disease Dalhousie University
Lakehead University Control
Jennifer Isenor Cecile Tremblay
Bill Cameron Dalhousie University Jeff Pernica Centre Hospitalier de
Ottawa Hospital Research McMaster University l’Université de Montréal
Institute and University of Jim Kellner
Ottawa University of Calgary Birahim Pierre Ndiaye Innocent Valea
Centre Muraz
Institut de Recherche en
Tobias Kollmann
Nicholas Chomont BC Children’s Hospital Santé, de Surveillance
Centre Hospitalier de Epidémiologique et de Otto Vanderkooi
L’Université de Montréal Mark Loeb Formations (IRESSEF) University of Calgary
McMaster University Brian Ward
Brenda Coleman Guillaume Poliquin McGill University
Mount Sinai Hospital Judy MacDonald Public Health Agency of
University of Calgary Canada and University of Duncan Webster
Jeannette Comeau Winnipeg Saint John Regional
Dalhousie University Souleymane Mboup Hospital
Institut de Recherche en Caroline Quach
Curtis Cooper Santé, de Surveillance Université Montreal
Ottawa Hospital Research
Institute and University of Epidémiologique et de Earl Rubin
Ottawa Formations (IRESSEF) McGill University
Janet McElhaney
Mark Dionne Health Sciences North and Manish Sadarangani
Université Laval University of British
Northern Ontario School of Columbia
Medicine

9